- Home
- IGD vs CKPT Comparison
IGD vs CKPT Comparison
Compare IGD & CKPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IGD
- CKPT
- Stock Information
- Founded
- IGD N/A
- CKPT 2014
- Country
- IGD United States
- CKPT United States
- Employees
- IGD N/A
- CKPT N/A
- Industry
- IGD Trusts Except Educational Religious and Charitable
- CKPT Biotechnology: Pharmaceutical Preparations
- Sector
- IGD Finance
- CKPT Health Care
- Exchange
- IGD Nasdaq
- CKPT Nasdaq
- Market Cap
- IGD 422.7M
- CKPT 361.1M
- IPO Year
- IGD N/A
- CKPT 2017
- Fundamental
- Price
- IGD $5.65
- CKPT N/A
- Analyst Decision
- IGD
- CKPT Buy
- Analyst Count
- IGD 0
- CKPT 3
- Target Price
- IGD N/A
- CKPT $4.33
- AVG Volume (30 Days)
- IGD 215.3K
- CKPT 2.1M
- Earning Date
- IGD 01-01-0001
- CKPT 05-13-2025
- Dividend Yield
- IGD 9.15%
- CKPT N/A
- EPS Growth
- IGD N/A
- CKPT N/A
- EPS
- IGD N/A
- CKPT N/A
- Revenue
- IGD N/A
- CKPT $41,000.00
- Revenue This Year
- IGD N/A
- CKPT $102,182.93
- Revenue Next Year
- IGD N/A
- CKPT $351.71
- P/E Ratio
- IGD N/A
- CKPT N/A
- Revenue Growth
- IGD N/A
- CKPT N/A
- 52 Week Low
- IGD $4.60
- CKPT $1.80
- 52 Week High
- IGD $5.26
- CKPT $4.50
- Technical
- Relative Strength Index (RSI)
- IGD 51.03
- CKPT 3.56
- Support Level
- IGD $5.63
- CKPT $4.14
- Resistance Level
- IGD $5.72
- CKPT $4.28
- Average True Range (ATR)
- IGD 0.05
- CKPT 0.02
- MACD
- IGD -0.01
- CKPT -0.50
- Stochastic Oscillator
- IGD 33.33
- CKPT 0.00
About IGD Voya Global Equity Dividend and Premium Opportunity Fund
Voya Global Equity Dividend and Premium Opportunity Fund are a United States-based diversified, closed-end Fund. The primary objective of the Fund is to seek to provide investors with a high level of income from a portfolio of common stocks with historically attractive dividend yields and premiums from call option writing. The secondary investment objective of the company is capital appreciation. Under normal market conditions, the Fund will invest at least 80% of its managed assets in a portfolio of common stocks of dividend-paying companies located throughout the world.
About CKPT Checkpoint Therapeutics Inc.
Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the USA. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR-related protein (GITR) and carbonic anhydrase IX (CAIX). The company is evaluating its small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor (EGFR) inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer.